229 related articles for article (PubMed ID: 22231447)
1. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.
Li X; Lu Y; Liang K; Hsu JM; Albarracin C; Mills GB; Hung MC; Fan Z
Oncogene; 2012 Oct; 31(40):4372-83. PubMed ID: 22231447
[TBL] [Abstract][Full Text] [Related]
2. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
Castro NE; Lange CA
Breast Cancer Res; 2010; 12(4):R60. PubMed ID: 20687930
[TBL] [Abstract][Full Text] [Related]
3. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
Lofgren KA; Ostrander JH; Housa D; Hubbard GK; Locatelli A; Bliss RL; Schwertfeger KL; Lange CA
Breast Cancer Res; 2011 Sep; 13(5):R89. PubMed ID: 21923922
[TBL] [Abstract][Full Text] [Related]
4. Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6.
Weaver AM; Silva CM
Breast Cancer Res; 2007; 9(6):R79. PubMed ID: 17997837
[TBL] [Abstract][Full Text] [Related]
5. Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.
Mizuguchi Y; Specht S; Isse K; Sasatomi E; Lunz JG; Takizawa T; Demetris AJ
J Hepatol; 2015 Aug; 63(2):399-407. PubMed ID: 25770659
[TBL] [Abstract][Full Text] [Related]
6. Brk/PTK6 signaling in normal and cancer cell models.
Ostrander JH; Daniel AR; Lange CA
Curr Opin Pharmacol; 2010 Dec; 10(6):662-9. PubMed ID: 20832360
[TBL] [Abstract][Full Text] [Related]
7. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
Ai M; Liang K; Lu Y; Qiu S; Fan Z
Cancer Biol Ther; 2013 Mar; 14(3):237-45. PubMed ID: 23291984
[TBL] [Abstract][Full Text] [Related]
8. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
[TBL] [Abstract][Full Text] [Related]
9. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
10. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
[TBL] [Abstract][Full Text] [Related]
12. Breast tumor kinase (Brk/PTK6) plays a role in the differentiation of primary keratinocytes.
Tupper J; Crompton MR; Harvey AJ
Arch Dermatol Res; 2011 May; 303(4):293-7. PubMed ID: 21240512
[TBL] [Abstract][Full Text] [Related]
13. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression.
Regan Anderson TM; Peacock DL; Daniel AR; Hubbard GK; Lofgren KA; Girard BJ; Schörg A; Hoogewijs D; Wenger RH; Seagroves TN; Lange CA
Cancer Res; 2013 Sep; 73(18):5810-20. PubMed ID: 23928995
[TBL] [Abstract][Full Text] [Related]
14. HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.
Ai M; Qiu S; Lu Y; Fan Z
Cell Signal; 2013 Sep; 25(9):1754-61. PubMed ID: 23707532
[TBL] [Abstract][Full Text] [Related]
15. BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.
Miah S; Goel RK; Dai C; Kalra N; Beaton-Brown E; Bagu ET; Bonham K; Lukong KE
PLoS One; 2014; 9(2):e87684. PubMed ID: 24523872
[TBL] [Abstract][Full Text] [Related]
16. Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes.
Kasprzycka M; Majewski M; Wang ZJ; Ptasznik A; Wysocka M; Zhang Q; Marzec M; Gimotty P; Crompton MR; Wasik MA
Am J Pathol; 2006 May; 168(5):1631-41. PubMed ID: 16651629
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
18. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
19. Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.
Tsui T; Miller WT
Biochemistry; 2015 May; 54(20):3173-82. PubMed ID: 25940761
[TBL] [Abstract][Full Text] [Related]
20. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]